Effect of Low Molecular Weight Heparin on Survival of Stage I, II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.
Latest Information Update: 05 Oct 2018
Price :
$35 *
At a glance
- Drugs Tinzaparin sodium (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TILT
- 27 Sep 2018 Results published in the European Respiratory Journal.
- 01 Sep 2016 Status changed from active, no longer recruiting to completed.
- 17 Dec 2010 Planned end date changed from 1 Jun 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.